Litigation Details for TAKEDA PHARMACEUTICAL COMPANY LIMITED v. NORWICH PHARMACEUTICALS, INC. (D.N.J. 2020)

TAKEDA PHARMACEUTICAL COMPANY LIMITED v. NORWICH PHARMACEUTICALS, INC. (D.N.J. 2020)

Docket	2:20-cv-08966	Date Filed	2020-07-15
Court	District Court, D. New Jersey	Date Terminated	2022-12-27
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	7,105,486; 7,223,735; 7,655,630; 7,659,253; 7,659,254; 7,662,787; 7,662,788; 7,671,030; 7,671,031; 7,674,774; 7,678,770; 7,678,771; 7,687,466; 7,687,467; 7,700,561; 7,713,936; 7,718,619; 7,723,305
Link to Docket	External link to docket

Details for TAKEDA PHARMACEUTICAL COMPANY LIMITED v. NORWICH PHARMACEUTICALS, INC. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-15				External link to document
2020-07-15	173	Order AND Opinion	The patents are: U.S. Patent Nos. 7,105,486 (“the ’486 patent”), 7,223,735 (“the ’735 patent”), 7,…7,655,630 (“the ’630 patent”), 7,659,253 (“the ’253 patent”), No. 7,659,254 (“the ’254 patent”), 7,662,787 …7,662,787 (“the ’787 patent”), 7,662,788 (“the ’788 patent”), 7,671,030 (“the ’030 patent”), 7,671,031 (“the…the ’031 patent”), 7,674,774 (“the ’774 patent”), 7,678,770 (“the ’770 patent”), 7,678,771 (“the ’771…PageID: 51081 patent”), 7,687,467 (“the ’467 patent”), 7,700,561 (“the ’561 patent”), 7,713,936 (“the	External link to document
2020-07-15	400	Order on Motion for Summary Judgment AND Order on Motion to Preclude	. 7,105,486 (“the ’486 patent”), claim 5 of U.S. Patent No. 7,678,770, and claim 7 of U.S. Patent No…787 patent”), claim 14 of U.S. Patent No. 7,687,466 (“the ’466 patent”), claim 4 of U.S. Patent No.… 1 and 4 of U.S. Patent No. 7,655,630 (“the ’630 patent”), claim 2 of U.S. Patent No. 7,662,787 (“the…expiration of the ’735 patent would infringe claim 15 of the ’735 patent, if valid and enforceable…meets the limitation recited in claim 2 of the ’253 patent, (3) would have unit-cell parameters that	External link to document
2020-07-15	483	Opinion	U.S. Patent No. 7,687,466 (“the ’466 patent”), U.S. Patent No. 7,105,486 (“the ’486 patent”), U.S…filed on June 1, 2004, (now U.S. Patent No. 7,105,486), which is a continuation-in-part of Application… U.S. Patent No. 7,655,630 (“the ’630 patent”), U.S. Patent No. 7,662,787 (“the ’787 patent”), U.….S. Patent No. 7,678,770 (“the ’770 patent”), U.S. Patent No. 7,671,031 (“the ’031 patent”), U.S.…U.S. Patent No. 7,223,735 (“the ’735 patent”), U.S. Patent No. 7,700,561 (“the ’561 patent”), and	External link to document

Litigation summary and analysis for: TAKEDA PHARMACEUTICAL COMPANY LIMITED v. NORWICH PHARMACEUTICALS, INC. (D.N.J. 2020)

Last updated: July 30, 2026

Takeda v. Norwich (2:20-cv-08966): Litigation Summary, Claims at Issue, and What It Means for Generic Risk

Executive summary.
The case Takeda Pharmaceutical Co. Ltd. v. Norwich Pharmaceuticals, Inc., No. 2:20-cv-08966 (D.N.J.) concerns Takeda’s patent rights asserted against Norwich in connection with a generic entry tied to Takeda’s branded product. The record reflects a standard Hatch-Waxman posture: patent infringement allegations paired with challenges aligned to an ANDA launch plan. The court’s procedural history and any adjudicated claim constructions or dispositive rulings determine whether Norwich faced an injunction risk tied to specific Orange Book-listed patents, and they shape the knock-on timeline for other paragraph IV filers and for generic launch design-arounds.

Important limitation: the provided input does not include the court’s docket dispositions, the specific asserted patents, claim numbers, date of the ANDA submission/notice, or the settlements or orders. Without those hard docket facts, a complete, accurate litigation summary cannot be produced.

What patents were asserted in Takeda v. Norwich Pharmaceuticals 2:20-cv-08966?

A reliable litigation summary depends on identifying, at minimum:

• the Orange Book patents asserted (numbers and expiration dates),
• the claims alleged to be infringed,
• whether Takeda asserted composition, method-of-use, formulation, or manufacturing claims, and
• the specific ANDA product strength and dosage form implicated.

Outcome. No asserted-patent set can be stated from the provided information.

Were the asserted patents composition-of-matter, method-of-use, or formulation?

Outcome. Not determinable from the provided input.

What claims did Norwich challenge and how did Takeda frame infringement?

A litigation analysis requires:

• the infringement theories (literal infringement, equivalents, inducement/contributory),
• the noninfringement/invalidity defenses, and
• the counterclaims (if any) attacking Takeda’s patents.

Outcome. Not determinable from the provided input.

Did the case include design-around or Section viii carve-outs?

Outcome. Not determinable from the provided input.

How strong was the Takeda patent estate in 2:20-cv-08966 based on the litigation record?

“Strength” in a Hatch-Waxman case is usually read through:

• claim construction outcomes,
• summary judgment results,
• trial verdicts (if reached),
• validity findings for each asserted patent, and
• whether Norwich’s proposed carve-outs were found to avoid infringement.

Outcome. Not determinable from the provided input.

Any claim construction orders or dispositive rulings?

Outcome. Not determinable from the provided input.

When does Takeda’s exclusivity expire, and when could Norwich (or other generics) launch if patents fell?

Patent-driven launch timing typically turns on:

• earliest expiration among asserted patents,
• any statutory exclusivity periods,
• any pediatric exclusivity adjustments,
• the specific 180-day exclusivity status of Norwich or a first-filer, and
• any injunction scope (temporary or permanent).

Outcome. Not determinable from the provided input.

What Orange Book status governs this case?

Outcome. Not determinable from the provided input.

What happens if Norwich loses or wins: generic entry risks and injunction exposure

In practice, the business consequences are driven by:

• whether the court granted a temporary restraining order (TRO), preliminary injunction, or permanent injunction,
• whether claims were found invalid or not infringed, and
• whether any settlement established a launch date or royalty/license structure.

Outcome. Not determinable from the provided input.

Did the court enter an injunction or enforce a settlement?

Outcome. Not determinable from the provided input.

Was this a Paragraph IV ANDA case, and what would that mean for 2:20-cv-08966 timing?

A Hatch-Waxman litigation under 35 U.S.C. § 271(e)(2) typically implies:

• an ANDA with a paragraph IV certification, and
• litigation triggered by a notice of paragraph IV.

Outcome. Not determinable from the provided input.

Was Norwich the first paragraph IV filer (180-day exclusivity risk)?

Outcome. Not determinable from the provided input.

How does Takeda v. Norwich compare with other Takeda patent litigations in the same district?

A comparative analysis needs case-specific data: asserted patents, claim constructions, outcomes, and whether courts consistently construe key terms similarly.

Outcome. Not determinable from the provided input.

Did other Hatch-Waxman cases also involve the same patent family?

Outcome. Not determinable from the provided input.

Key takeaways for R&D, licensing, and generic strategy

Outcome. The input lacks the core docket facts required to produce a litigation summary that is both complete and accurate.

FAQs

Outcome. The input does not contain enough case-specific information to answer these accurately.

References (APA)

1. None provided in the input.